FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Fitb: Q1 Results Dominated By The Comerica Acquisition

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

FITB posted mixed Q1 2026 results, with operating EPS of $0.83 vs. $0.73 prior year, in line with consensus, while revenue of $2.8B (+21%) also met expectations. Results reflect the successful February 1 closure of the $12.7B Comerica acquisition, bringing $51B in loans and $65B in deposits. The acquisition meaningfully improved credit quality, with the NCO ratio declining to 37 bps from 40 bps, marking the lowest level in two years, while nonperforming assets also declined, with the NPA ratio falling to 57 bps from 65 bps. Management highlighted successful retention of key customer-facing colleagues and early revenue synergies across commercial and consumer businesses. Net interest income surged 26% Q/Q to $1.939B, reflecting Comerica contributions and lower funding costs. However, operating metrics were significantly impacted by $635M in merger-related charges, representing approximately half of expected full-year costs, while the CET1 capital ratio declined to 9.96% from 10.81% due to acquisition impacts.

Related Articles

Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Dell Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our price target from $166 to $239, 16x our FY 28 (Jan.) EPS view, above DELL's three-year average (~11x) on AI upside. We raise our FY 27 EPS view by $0.31 to $12.80 and FY 28's by $0.49 to $14.91. Global AI data center spending continues to strengthen, and we expect DELL will continue capitalizing on this momentum as it builds its reputation in the AI server space. We also think server peer SMCI's recent export control issues could see some of its non-hyperscaler business shift toward DELL, providing upside to recent guidance, while recent takeover rumors (despite being denied by NVDA) highlight DELL's value as a critical infrastructure provider and provide further support for an above-historical multiple. The ongoing memory shortage remains a key risk, but with supply fully secured to support FY 27 guidance, we doubt a significant hit to the company's near-term margin outlook. We expect its relationship with memory makers will allow for favorable supply allocation vs. peers next year as well.

$DELL
Research

Research Alert: Vale S.a. Posts Strong Q1 2026 Operating Results

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vale posted solid Q1 2026 (operating) results, with iron ore production of 69.7Mt (+3.0% Y/Y) and energy transition metals delivering double-digit growth, including copper at 102.3kt (+12.5% Y/Y) and nickel at 49.3kt (+12.3% Y/Y). The performance marked multiyear highs across core assets, with S11D achieving another record and Southeastern System surging 19.2% driven by Capanema's ramp-up. We view the operational momentum as validation of Vale's capital strategy and positioning for long-term value creation in energy transition metals. Management maintained 2026 guidance, expecting upper end of 335Mt-345Mt iron ore targets as Capanema reaches full capacity. Copper realizations surged 47.8% Y/Y to $13,143/t while iron ore premiums expanded 29.2%, demonstrating portfolio optimization benefits. We believe base metals are becoming increasingly important value drivers as Novo Carajas advances, though key watch items include project execution and iron ore premium sustainability.

$VALE
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Albertsons Companies, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target at $21, based on 8.8x our FY 27 (Feb.) EPS of $2.38 (raised from $2.36; FY 28 initiated at $2.64). This multiple is near its long-term mean of 9.1x but remains a discount to its closest publicly-traded peer Kroger (~13x). Pharmacy headwinds from the Inflation Reduction Act are weighing on identical sales this fiscal year, though they are benefiting margins through a mix shift toward higher-margin generics. Margins should also improve with better digital profitability, easing GLP-1 pressure, and ongoing productivity initiatives. We expect identical sales growth to remain pressured in May-Q due to egg deflation, with both growth and profitability improving in subsequent quarters. We also believe ACI's investments in value, including lower prices and targeted promotions, should begin to drive an improvement in core grocery trends as the year progresses. Our Buy view reflects double-digit total shareholder return potential, including share repurchases and a ~4% dividend yield.

$ACI